BACKGROUND: Azithromycin is frequently used to treat shigellosis; however, clinical outcomes are uncertain. METHODS: We performed an observational cohort study in Bangladesh of patients with invasive diarrhea treated empirically with azithromycin. Susceptibility testing was performed by broth microdilution and disk diffusion post hoc on all Shigella isolates and clinical response was correlated with in vitro susceptibility. RESULTS: There were 149 Shigella culture-positive patients in the primary analysis. Infection with Shigella with decreased susceptibility to azithromycin was significantly associated with persistence of diarrhea at day 5 (31% vs 12%; relative risk [RR], 2.66; 95% confidence interval [CI], 1.34-5.28), culture positivity at day 5 or 6 (35% vs 5%; RR, 5.26; 95% CI, 1.84-14.85), and a higher rate of overnight hospitalization (58% vs 39%; RR, 1.49; 95% CI, 1.06-2.09). Shigella flexneri was more common than Shigella sonnei (58% vs 36%); however, S. sonnei constituted most of the isolates with decreased susceptibility to azithromycin (67%) and most of the multidrug-resistant strains (54%); thus, poor clinical outcomes were associated with S. sonnei. The current epidemiological cutoff for S. flexneri of ≥16 µg/mL to define decreased susceptibility to azithromycin was clinically predictive of poor outcome. Patients with S. sonnei and a low MIC (4 µg/mL) still had elevated rates of persistent diarrhea and culture positivity. CONCLUSIONS: This study documents worse clinical outcomes for S. flexneri with decreased susceptibility to azithromycin, as well as S. sonnei, and supports the utility of susceptibility testing and clinical breakpoints for azithromycin. S. sonnei is an emerging drug-resistant threat. CLINICAL TRIALS REGISTRATION: NCT03778125.
BACKGROUND:Azithromycin is frequently used to treat shigellosis; however, clinical outcomes are uncertain. METHODS: We performed an observational cohort study in Bangladesh of patients with invasive diarrhea treated empirically with azithromycin. Susceptibility testing was performed by broth microdilution and disk diffusion post hoc on all Shigella isolates and clinical response was correlated with in vitro susceptibility. RESULTS: There were 149 Shigella culture-positive patients in the primary analysis. Infection with Shigella with decreased susceptibility to azithromycin was significantly associated with persistence of diarrhea at day 5 (31% vs 12%; relative risk [RR], 2.66; 95% confidence interval [CI], 1.34-5.28), culture positivity at day 5 or 6 (35% vs 5%; RR, 5.26; 95% CI, 1.84-14.85), and a higher rate of overnight hospitalization (58% vs 39%; RR, 1.49; 95% CI, 1.06-2.09). Shigella flexneri was more common than Shigella sonnei (58% vs 36%); however, S. sonnei constituted most of the isolates with decreased susceptibility to azithromycin (67%) and most of the multidrug-resistant strains (54%); thus, poor clinical outcomes were associated with S. sonnei. The current epidemiological cutoff for S. flexneri of ≥16 µg/mL to define decreased susceptibility to azithromycin was clinically predictive of poor outcome. Patients with S. sonnei and a low MIC (4 µg/mL) still had elevated rates of persistent diarrhea and culture positivity. CONCLUSIONS: This study documents worse clinical outcomes for S. flexneri with decreased susceptibility to azithromycin, as well as S. sonnei, and supports the utility of susceptibility testing and clinical breakpoints for azithromycin. S. sonnei is an emerging drug-resistant threat. CLINICAL TRIALS REGISTRATION: NCT03778125.
Authors: Suporn Pholwat; Jie Liu; Mami Taniuchi; Rashidul Haque; Mohammed Masud Alam; Abu Syed Golam Faruque; Tahsin Ferdous; Rifat Ara; James A Platts-Mills; Eric R Houpt Journal: J Clin Microbiol Date: 2021-10-20 Impact factor: 11.677
Authors: Radhika Gharpure; Cindy R Friedman; Veronica Fialkowski; Jennifer P Collins; Jonathan Strysko; Zachary A Marsh; Jessica C Chen; Elizabeth H Meservey; Azizat A Adediran; Morgan N Schroeder; Ashutosh Wadhwa; Kathleen E Fullerton; Louise Francois Watkins Journal: Clin Infect Dis Date: 2022-02-11 Impact factor: 9.079
Authors: Jie Liu; Suporn Pholwat; Jixian Zhang; Mami Taniuchi; Rashidul Haque; Masud Alam; John Benjamin Ochieng; Jennifer A Jones; James A Platts-Mills; Sharon M Tennant; Eric Houpt Journal: J Clin Microbiol Date: 2021-01-21 Impact factor: 5.948
Authors: Jeffrey M Pernica; Tonya Arscott-Mills; Andrew P Steenhoff; Margaret Mokomane; Banno Moorad; Mbabi Bapabi; Kwana Lechiile; Oarabile Mangwegape; Boswa Batisani; Norah Mawoko; Charles Muthoga; Thuvaraha Vanniyasingam; Joycelyne Ewusie; Amy Lowe; Janice M Bonsu; Alemayehu M Gezmu; Marek Smieja; Loeto Mazhani; Ketil Stordal; Lehana Thabane; Matthew S Kelly; David M Goldfarb Journal: BMJ Glob Health Date: 2022-04
Authors: James A Platts-Mills; Elias G Ayoub; Jixian Zhang; Elizabeth T Rogawski McQuade; Ahmed M Arzika; Ramatou Maliki; Amza Abdou; Jeremy D Keenan; Thomas M Lietman; Jie Liu; Eric R Houpt Journal: Clin Infect Dis Date: 2022-08-31 Impact factor: 20.999